Sunday November 08 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Cannabinoid Market Forecasts and Analysis to 2012

Cannabinoid Market Forecasts and Analysis to 2012

With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.

4 drugs already available:

Marinol

Nabilone

Sativex

Rimonabant

With indications for the control of chemotherapy-induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia associated with HIV/AIDS.

The worlds first whole-cannabis plant extract, Sativex was developed by GW. The approval of Sativex upon the Canadian neuropathic pain associated Multiple Sclerosis market was in 2005, Sativex is expected to help the market with its additional indications and its introduction to Europe and the US.

The profile of the market is set to be raised considerably due to the launch of Rimonabant by Sanofi-Aventis for obesity. The fact that the drug is imminent in the US and EU, will further push its success to blockbuster status. With such important developments within the cannabinoid market, cannabinoids become pharmaceutical products rather than political products and will further ensure increased R&D efforts into this market. Major Pharma will not sit around and watch blockbusters being created without wanting to be part of the success. Will you be part of the success?

Visiongain values today’s cannabinoid market at $0.7095 billion. This has grown 45.5% from 2006's revenues of $0.3867 billion. Visiongain predicts the growth of the market will continue over the forecast period to 2012. Our accurate projections within this report, suggest excellent prospects for the cannabinoid market as a whole.

Designed as a critical business aid, Cannabinoids Market Forecasts & Analysis to 2012 provides the industry's leading evaluation of the market. Now in its 2nd edition, the report focuses on the following aspects:

Potential Cannabinoid Therapies

The Worldwide Cannabinoid Market- Current and

Future Products

Pipeline Cannabinoid Products

Company Information

Market Activity

Forecasts to 2012

Regulatory Issues of Cannabinoids and Medically

Approved Cannabis in the eight Major Markets

Alternative therapeutic areas - maximising revenue through alternative indications

The report provides in-depth market analysis for current and potential products. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research and highlighting new indications. The study also assesses the challenges faced by potential companies. Attitudes to cannabinoids are changing - a blockbuster is set to happen.

Why You Must Buy This Report:

This 190+ paged report features 26 tables, 42 graphs and figures, news, insights, the very latest developments and an in depth review of the cannabinoids market with up to date analysis. This report is a vital addition to gaining an understanding of this growing sector of the pharmaceutical market, and will give your company 'the edge' over your competitors. You can not afford to be without this latest report from visiongain.

Five key questions this report answers are:

What is the market potential for cannabinoids treating various diseases?

What latest clinical trials/experimental research has been performed to develop cannabinoids for therapeutic uses?

What is the global cannabinoid market value of today and the future worth?

How the cannabinoid market will gain blockbuster status and why?

What are the regulatory issues surrounding cannabinoids and medicinal cannabis use in the eight major markets?

Methodology

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic institutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers.

Unique benefits to you when you order this report

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using hard drive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication Date: 22/03/07

Pages: 199

PDF Format
Table of Contents

Price
Single Use Licence $2500.00
Department Licence 5 Users $5000.00
Company-wide Intranet Licence $8750.00
Company over 2500 employees $11750.00

Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.

Back to top